Statements (57)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:Company
|
| gptkbp:bfsLayer |
5
|
| gptkbp:bfsParent |
gptkb:Dräger_Group
|
| gptkbp:acquisition |
Xenon Acquisition Name
|
| gptkbp:awards |
Xenon Award Name
|
| gptkbp:benefits |
Xenon Employee Benefits Description
|
| gptkbp:business_model |
Xenon Business Model Description
|
| gptkbp:ceo |
Xenon CEO Name
|
| gptkbp:clinical_trial |
Xenon Clinical Development Program Name
Xenon Clinical Trial Name Xenon Research Program Name |
| gptkbp:collaborations |
Xenon Collaboration Name
|
| gptkbp:committee |
Xenon Advisory Board Name
|
| gptkbp:community_engagement |
Xenon Community Program Name
|
| gptkbp:cultural_representation |
Xenon Diversity Program Name
|
| gptkbp:employees |
Xenon Employee Count
|
| gptkbp:financial_performance |
Xenon Annual Report Name
|
| gptkbp:financial_products |
Xenon Financial Report Name
|
| gptkbp:founded |
gptkb:1996
|
| gptkbp:founder |
Xenon Founder Name
|
| gptkbp:global_presence |
Xenon Global Presence Description
|
| gptkbp:governed_by |
Xenon Governance Structure
|
| gptkbp:headquarters |
gptkb:San_Diego,_California
|
| https://www.w3.org/2000/01/rdf-schema#label |
Xenon Corporation
|
| gptkbp:industry |
gptkb:Company
|
| gptkbp:innovation |
Xenon Innovation Program Name
|
| gptkbp:invention |
Xenon Patent Name
|
| gptkbp:investment |
Xenon Investment Amount
Xenon Investor Name Xenon Shareholder Meeting Date |
| gptkbp:key_people |
Xenon Key Person Name
|
| gptkbp:language_of_instruction |
Xenon Pipeline Name
|
| gptkbp:location |
gptkb:North_America
|
| gptkbp:market_cap |
Xenon Market Cap Amount
|
| gptkbp:mission |
Transforming lives through innovative medicines.
|
| gptkbp:parent_company |
Xenon Parent Company Name
|
| gptkbp:partnership |
Xenon Partner Company Name
|
| gptkbp:partnerships |
Xenon Partnership Name
|
| gptkbp:philanthropy |
Xenon Philanthropic Initiative Name
|
| gptkbp:products |
Xenon Pharmaceuticals
|
| gptkbp:regulatory_compliance |
Xenon Approval Name
|
| gptkbp:research_areas |
Xenon Therapeutic Area Name
|
| gptkbp:research_focus |
Rare Diseases
|
| gptkbp:revenue |
Xenon Revenue Amount
|
| gptkbp:risk_factor |
Xenon Risk Management Strategy
|
| gptkbp:services |
Drug Development
|
| gptkbp:social_responsibility |
Xenon CSR Program Name
|
| gptkbp:stock_exchange |
gptkb:NASDAQ
|
| gptkbp:strategic_importance |
Xenon Strategic Goal Name
|
| gptkbp:subsidiary |
Xenon Subsidiary Name
|
| gptkbp:sustainability_initiatives |
Xenon Sustainability Program Name
|
| gptkbp:symbol |
XENE
|
| gptkbp:team |
Xenon Leadership Team Name
|
| gptkbp:technology |
Xenon Technology Name
|
| gptkbp:trademark |
Xenon Trademark Name
|
| gptkbp:vision |
To be a leader in the development of innovative therapies.
|
| gptkbp:website |
www.xenon-pharma.com
|